CU20110133A7 - Derivados de (4-terc-butilpiperazin-2-il)(piperazin-1-il)metanona-n-carboxamida - Google Patents

Derivados de (4-terc-butilpiperazin-2-il)(piperazin-1-il)metanona-n-carboxamida

Info

Publication number
CU20110133A7
CU20110133A7 CU20110133A CU20110133A CU20110133A7 CU 20110133 A7 CU20110133 A7 CU 20110133A7 CU 20110133 A CU20110133 A CU 20110133A CU 20110133 A CU20110133 A CU 20110133A CU 20110133 A7 CU20110133 A7 CU 20110133A7
Authority
CU
Cuba
Prior art keywords
butilpiperazin
metanona
carboxamida
terc
piperazin
Prior art date
Application number
CU20110133A
Other languages
English (en)
Inventor
David Waterson
Alan Wellington Faull
John Cumming
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CU20110133A7 publication Critical patent/CU20110133A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I) ESPACIO PARA LA FÓRMULA Los compuestos actúan a través del antagonismo del receptor CCR2b y pueden utilizarse para tratar una enfermedad inflamatoria y/o el dolor neuropático.
CU20110133A 2008-12-15 2011-06-15 Derivados de (4-terc-butilpiperazin-2-il)(piperazin-1-il)metanona-n-carboxamida CU20110133A7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12244508P 2008-12-15 2008-12-15

Publications (1)

Publication Number Publication Date
CU20110133A7 true CU20110133A7 (es) 2012-01-31

Family

ID=42241254

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20110133A CU20110133A7 (es) 2008-12-15 2011-06-15 Derivados de (4-terc-butilpiperazin-2-il)(piperazin-1-il)metanona-n-carboxamida

Country Status (24)

Country Link
US (3) US20100152197A1 (es)
EP (2) EP2727913A1 (es)
JP (1) JP2012512153A (es)
KR (1) KR20110099012A (es)
CN (1) CN102317273A (es)
AR (1) AR074737A1 (es)
AU (1) AU2009327575B2 (es)
BR (1) BRPI0922439A2 (es)
CA (1) CA2746990A1 (es)
CL (1) CL2011001436A1 (es)
CO (1) CO6440554A2 (es)
CR (1) CR20110332A (es)
CU (1) CU20110133A7 (es)
DO (1) DOP2011000191A (es)
EA (1) EA201190019A1 (es)
EC (1) ECSP11011131A (es)
IL (1) IL213163A0 (es)
MX (1) MX2011006087A (es)
NI (1) NI201100125A (es)
PE (1) PE20120082A1 (es)
TW (1) TW201028400A (es)
UY (1) UY32321A (es)
WO (1) WO2010071567A1 (es)
ZA (1) ZA201105219B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0519288A2 (pt) * 2004-12-24 2009-01-06 Astrazeneca Ab compostos heterocÍclicos como antagonistas de ccr2b
GB0525957D0 (en) * 2005-12-21 2006-02-01 Astrazeneca Ab Methods
WO2018134731A1 (en) 2017-01-17 2018-07-26 Glaxosmithkline Intellectual Property Development Limited Non peptidic heterobivalent molecules for treating inflammatory diseases
US12319958B2 (en) 2020-07-21 2025-06-03 Rutgers, The State University Of New Jersey Method and kit for CCR2 expression profiling and disease stratification

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133061A (en) * 1962-11-13 1964-05-12 Sterling Drug Inc Piperidine carboxamides and derivatives thereof
US3541085A (en) * 1969-05-09 1970-11-17 American Cyanamid Co Method of preparing thiotricyclic compounds
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
DE19743435A1 (de) * 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
US20060205761A1 (en) 2003-06-06 2006-09-14 Catherine Abbadie Ccr-2 antagonists for treatment of neuropathic pain
GB0428327D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Ab Method
BRPI0519288A2 (pt) * 2004-12-24 2009-01-06 Astrazeneca Ab compostos heterocÍclicos como antagonistas de ccr2b
GB0525957D0 (en) * 2005-12-21 2006-02-01 Astrazeneca Ab Methods

Also Published As

Publication number Publication date
ZA201105219B (en) 2012-03-28
EP2379519A1 (en) 2011-10-26
EA201190019A1 (ru) 2012-02-28
EP2727913A1 (en) 2014-05-07
ECSP11011131A (es) 2011-07-29
IL213163A0 (en) 2011-07-31
CO6440554A2 (es) 2012-05-15
MX2011006087A (es) 2011-06-21
DOP2011000191A (es) 2011-07-15
US20120289513A1 (en) 2012-11-15
CL2011001436A1 (es) 2011-08-26
CR20110332A (es) 2011-08-05
AU2009327575A1 (en) 2011-06-23
WO2010071567A1 (en) 2010-06-24
BRPI0922439A2 (pt) 2017-06-06
AU2009327575B2 (en) 2013-07-04
US20130289043A1 (en) 2013-10-31
PE20120082A1 (es) 2012-03-04
KR20110099012A (ko) 2011-09-05
JP2012512153A (ja) 2012-05-31
EP2379519A4 (en) 2012-06-20
NI201100125A (es) 2012-03-19
UY32321A (es) 2010-07-30
TW201028400A (en) 2010-08-01
CN102317273A (zh) 2012-01-11
AR074737A1 (es) 2011-02-09
US20100152197A1 (en) 2010-06-17
CA2746990A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
SV2011003884A (es) Arilpirrolidinas pesticidas
UY32379A (es) Derivados de n-heteroarilo sulfonammida sustituidos, sales, solvatos o tautómero farmacéuticamente aceptables, procesos de preparación, intermedios, composicones conteniéndolos y aplicaciones.
UY33238A (es) "Compuestos en calidad de antagonistas de bradiquinina-b1"
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
ECSP11011151A (es) Compuestos purina
DOP2012000006A (es) Agonista de gpr119
EA201170151A1 (ru) Пиперидиниловые агонисты gpcr
NI201100049A (es) Compuestos orgánicos.
SV2010003472A (es) Compuestos de pirazol
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
CU24335B1 (es) Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer
UY32110A (es) Inhibidores de aminopirimidina de los receptores de histamina para el tratamiento de una enfermedad
UY32111A (es) Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
UY32730A (es) Inhibidores de cyp17
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
UY32640A (es) Aril-pirimidinas como inhibidoras de sintasa dfe aldosterona
CU20110113A7 (es) Lactamas como inhibidores beta secretasa
DOP2011000191A (es) Derivados de (4-terc-butilpiperazin-2-il)(piperazin-1-il) metanona-n-carboxamida
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
NI200900154A (es) Nuevos procedimiento de obtención de la forma cristalina v de la agomelatina
UY34316A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
AR063799A1 (es) Profarmacos de penem